Business & Regulation

Patients don’t always read drug risk information – even when they say they do

A podcast series lets listeners eavesdrop on a conversation between scientists in a bar

What impact will Brexit, a new US President, and a flood of new technologies have on the industry?

Steve Keen talks to us about Trump, China, free trade and globalization

The players and chips are ready, what can poker teach us about the biosimilars business?

Big pharma CEOs should be wary of because orphans are usually better off alone.

Sitting Down With... Carol Lynch, Global Head Biopharmaceuticals, Sandoz.

The EMA says “yes” to transparency, but some pharma companies have other ideas.

A consortium of vendors and pharma companies search for a single, serialization standard.

Are reduced GDUFA fees on the horizon for contract manufacturers?